WO2006046065A1 - Botulinum toxin therapy of heart rhythm disorders - Google Patents
Botulinum toxin therapy of heart rhythm disorders Download PDFInfo
- Publication number
- WO2006046065A1 WO2006046065A1 PCT/GB2005/004182 GB2005004182W WO2006046065A1 WO 2006046065 A1 WO2006046065 A1 WO 2006046065A1 GB 2005004182 W GB2005004182 W GB 2005004182W WO 2006046065 A1 WO2006046065 A1 WO 2006046065A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- botulinum toxin
- botulinum
- disorders
- use according
- toxin type
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 41
- 229940053031 botulinum toxin Drugs 0.000 title claims abstract description 13
- 230000033764 rhythmic process Effects 0.000 title claims description 13
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- 239000000126 substance Substances 0.000 claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 230000002232 neuromuscular Effects 0.000 claims abstract description 23
- 230000003518 presynaptic effect Effects 0.000 claims abstract description 23
- 230000000903 blocking effect Effects 0.000 claims abstract description 22
- 206010003658 Atrial Fibrillation Diseases 0.000 claims abstract description 15
- 206010061592 cardiac fibrillation Diseases 0.000 claims abstract description 11
- 230000002600 fibrillogenic effect Effects 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 4
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims description 22
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 14
- 229940094657 botulinum toxin type a Drugs 0.000 claims description 14
- 108010074523 rimabotulinumtoxinB Proteins 0.000 claims description 7
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 108010069038 botulinum toxin type F Proteins 0.000 claims description 3
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 3
- JIWUESGGKYLPPG-UHFFFAOYSA-N 2-[4-[4-(2-hydroxy-4,4-dimethyl-2-morpholin-4-iumyl)phenyl]phenyl]-4,4-dimethyl-2-morpholin-4-iumol Chemical compound C1[N+](C)(C)CCOC1(O)C1=CC=C(C=2C=CC(=CC=2)C2(O)OCC[N+](C)(C)C2)C=C1 JIWUESGGKYLPPG-UHFFFAOYSA-N 0.000 claims description 2
- GZBUMTPCIKCWFW-UHFFFAOYSA-N triethylcholine Chemical compound CC[N+](CC)(CC)CCO GZBUMTPCIKCWFW-UHFFFAOYSA-N 0.000 claims description 2
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 claims description 2
- 229960001844 tubocurarine Drugs 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 description 19
- 238000011282 treatment Methods 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 7
- 239000003053 toxin Substances 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002723 toxicity assay Methods 0.000 description 3
- 208000004041 Gustatory Sweating Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108700017751 botulinum toxin type C Proteins 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000037315 hyperhidrosis Effects 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 101710195183 Alpha-bungarotoxin Proteins 0.000 description 1
- 206010059237 Auriculotemporal syndrome Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000014526 Conduction disease Diseases 0.000 description 1
- 206010063006 Facial spasm Diseases 0.000 description 1
- 201000001678 Frey syndrome Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003131 biological toxin Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940098753 dysport Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000007830 familial atrial fibrillation Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229940112646 myobloc Drugs 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000037392 palmar hyperhidrosis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 239000000664 voltage gated sodium channel blocking agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Definitions
- the instant invention relates to the use of a pre-synaptic neuromuscular blocking substance for preparing a medicament intended to treat or prevent heart fibrillation disorders.
- botulinum toxin is the most lethal natural biological agent known to man. About 50 picograms of a commercially available botulinum toxin type A (purified neurotoxin complex) correspond to the LD 50 in mice. However, the same toxin has been used at tiny doses for therapeutic purposes in man since the 1980s. To date, it is believed to treat a number of disorders among which can be mentioned the following: blepharospasm, hemifacial spasm, cervical dystonia, cerebral palsy, post- stroke spasticity of the arm or leg, hyperhidrosis (e.g.
- palmar hyperhidrosis palmar hyperhidrosis
- axillar hyperhidrosis Frey's syndrome or gustatory sweating
- wrinkles e.g. glabellar lines
- urinary retention urinary incontinence
- benign prostatic hyperplasia anal, fissure
- skin wounds type 2 diabetes, articular pathologies, acne and many others.
- botulinum toxins share the same therapeutic properties of botulinum toxin type A (e.g. botulinum toxins of types B, C 1 , D, E, F and G); however, only bot ⁇ linum toxin type A and botulinum toxin type B are currently marketed.
- Botulinum toxin type A is mainly commercially available from Ipsen (Dysport ® , Ipsen Limited, Slough, UK) and Allergan (BOTOX ® , Allergan Inc., Irvine, CA, USA) whereas botulinum toxin type B is sold by Elan (Myobloc ® /Neurobloc ® , Solstice Neurosciences Inc., San Diego, CA, USA).
- PCT patent application WO 03/084567 (or US patent 6,767,544) teaches the use of botulinum toxin to treat a cardiovascular disorder by administering an effective amount of a bot ⁇ linum toxin directly to a blood vessel of a patient (notably to prevent restenosis).
- cardiac is defined as "pertaining to blood vessels, for example, blood vessels of the heart”.
- pre-synaptic neuromuscular blocking substance and in particular a botulinum toxin, could also be used for the treatment or prevention of heart rhythm disorders, notably heart fibrillation disorders.
- pre-synaptic neuromuscular blocking substance should be understood in the present application a substance that prevents and/or inhibits transmission of the chemical messages and signals involved in pre-synaptic neuromuscular activity.
- pre-synaptic neuromuscular blocking substances are substances that inhibit acetylcholine (ACh) synthesis or release; those include notably biological toxins (such as botulinum neurotoxins and bungarotoxins but also any synthetic analogue thereof having the same activity like recombinantly engineered botulinum toxins) and chemicals (such as hemicholinium or triethylcholine which inhibit ACh synthesis, aminoglycoside antibiotics which inhibit ACh release or tubocurarine and similar compounds).
- Preferred pre-synaptic neuromuscular blocking substances according to this invention will be botulinum neurotoxins and bungarotoxins ( ⁇ -bungarotoxin being preferred among the bungarotoxins).
- botulinum neurotoxins or botulinum toxins
- botulinum neurotoxin complexes whether of type A, B, C, D, E, F or G
- high purity botulinum neurotoxins whether of type A, B, C, D, E, F or G
- any recombinantly engineered botulinum toxin having similar or better properties than the naturally occurring botulinum toxins or the purified forms thereof.
- Botulinum toxin type A includes all types of botulinum toxin type A, including A 1 , A 2 and A 3
- botulinum toxin type C includes all types of botulinum toxin type C, including C 1 or C 2 ; the same applies mutatis mutandis to the other serotypes of toxins.
- botulinum neurotoxin complex (whether of type A, B, C, D, E, F or G) should be understood in the present application a botulinum neurotoxin (whether of type A, B, C, D, E, F or G) associated with at least another non-toxic protein.
- botulinum neurotoxin (whether of type A, B, C, D, E, F or G) is meant, in the present application, botulinum neurotoxin (whether of type A, B, C, D, E, F or G) outside from complexes including at least another protein.
- a high purity botulinum neurotoxin (type A, B, C, D, E, F or G) does not contain significant quantities of any other Clostridium spp derived protein than botulinum neurotoxin (type A, B, C, D, E, F or G).
- the pre-synaptic neuromuscular blocking substance will be a botulinum toxin. More preferably, the botulinum toxin will be selected from the group consisting of botulinum toxin type A, botulinum toxin type B and botulinum toxin type F. Even more preferably, the botulinum toxin will be selected from the group consisting of botulinum toxin type A and botulinum toxin type B. In particular, the botulinum toxin will be botulinum toxin type A.
- the heart rhythm disorders are preferably heart fibrillation disorders. Heart fibrillation disorders are preferably selected from the group consisting of atrial fibrillation and ventricular fibrillation.
- the heart fibrillation disorder intended to be treated or prevented is atrial fibrillation.
- Atrial fibrillation can manifest several ways. Older people typically get chronic atrial fibrillation. Excess adrenaline causes adrenergic atrial fibrillation. Neurogenic atrial fibrillation stems from an imbalance in the nervous system's regulation of the heart. Men between 30 and 50 are subject to vagal atrial fibrillation after a meal or at rest. Young people can be affected by lone or primary atrial fibrillation, which presents no identifiable cause; paroxysmal atrial fibrillation, which causes intermittent attacks of variable length; and rare familial atrial fibrillation. Atrial fibrillation may also be associated with other cardiac muscles or valvula disorders such as cardiomyopathy, cardiac insufficiency, ischemia and/or infarction disorders (e.g. aortic, tricuspid, pulmonary or mitral valvula stenosis) or insufficiency or conduction disorders.
- cardiomyopathy cardiac insufficiency
- ischemia and/or infarction disorders e.g. aortic,
- the heart fibrillation disorder intended to be treated or prevented is ventricular fibrillation.
- the administration locus for the pre-synaptic neuromuscular blocking substance should be the location of the source of the irregular rhythm. In order to find said source, one could for example perform an electrophysiological study.
- the pre-synaptic neuromuscular blocking substance is used to treat the fibrillation disorder.
- a pre-synaptic neuromuscular blocking substance with short onset of action like voltage-gated sodium channel blockers will be preferred.
- the pre-synaptic neuromuscular blocking substance is used to prevent recurrence of the fibrillation disorder.
- a pre-synaptic neuromuscular blocking substance with a prolonged duration of action e.g. botulinum toxin type A or botulinum toxin type F, and preferably botulinum toxin type A
- botulinum toxin type A e.g. botulinum toxin type A or botulinum toxin type F, and preferably botulinum toxin type A
- pre-synaptic neuromuscular blocking substance which shall be needed for the treatment of the disorders mentioned above varies depending on the disorder to be treated, administration mode, age and body weight of the patient to be treated and health state of the latter, and it is the treating physician or veterinary that will eventually make the decision.
- Such a quantity determined by the treating physician or veterinarian is called here "therapeutically efficient quantity”.
- LD 50 should be understood in the present application the median intraperitoneal dose in mice injected with botulinum neurotoxin complex (type A, B, C, D 5 E 5 F or G) or high purity botulinum neurotoxin (type A 5 B, C 5 D 5 E 5 F or G) that causes death of half of said mice within 96 hours (see the "Mouse toxicity assay” protocol under "ANALYTICAL METHODS").
- botulinum toxin type A 5 this effective amount could be about 10 to 500 LD 50 units and preferably about 50 to 250 LD 50 units:
- pre-synaptic neuromuscular blocking substance treatment according to the instant invention may be combined with the other current treatments of heart rhythm disorders (such as pacemaker, anticoagulants or other common medications for the treatment of heart rhythm disorders).
- heart rhythm disorders such as pacemaker, anticoagulants or other common medications for the treatment of heart rhythm disorders.
- the pre-synaptic neuromuscular blocking substance treatment may optionally be associated with an analgesic treatment (e.g. by administration of an analgesic substance like morphine) prior to, at the same time or shortly after the toxin is administered.
- an analgesic treatment e.g. by administration of an analgesic substance like morphine
- about X means an interval from X minus 10% of X to X plus 10% of X, and preferably an interval from X minus 5% of X to X plus 5% of X and about "about X to Y” means an interval from X minus 10% ' of (X+Y) to Y plus 10% of (X+Y), and preferably an interval from X minus 5% of (X+Y) to Y plus 5% of (X+Y).
- a male patient in his sixties has had several episodes of atrial fibrillation.
- An electrophysiological study is performed to determine the location of the source of the irregular rhythm.
- Injection of 80 LD 50 units of a botulinum toxin type A preparation e.g. Dy sport ® from Ipsen Ltd, Slough, UK - the product being used following the reconstitution protocol of the manufacturer
- the arrhythmic episodes were eliminated for a period of at least three months.
- a mouse toxicity assay can be used to measure the toxicity of botulinum neurotoxin complex (type A, B, C, D, E, F or G) or high purity botulinum neurotoxin (type A, B, C, D, E, F or G).
- a standard diluent will be used to prepare a range of dilutions at or about the estimated LD 50 value. The range and scale of dilutions is arranged so as to establish an accurate LD 50 value.
- mice are injected intraperitoneally with a known arid standardised volume of diluted toxin. After 96 hours, the number of deaths and survivors in each dilution group will be recorded. The LD 50 value is the median dose which kills half of the injected animals within 96 hours.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The instant invention relates to the use of a pre-synaptic neuromuscular blocking substance for preparing a medicament intended to treat or prevent heart fibrillation disorders. Preferably, the pre-synaptic neuromuscular blocking substance will be a botulinum toxin. Preferably also, the heart fibrillation disorder to be treated of prevented will be atrial fibrillation.
Description
BOTULINUM TOXIN THERAPY OF HEART RHYTHM DISORDERS
The instant invention relates to the use of a pre-synaptic neuromuscular blocking substance for preparing a medicament intended to treat or prevent heart fibrillation disorders.
Among pre-synaptic neuromuscular blocking substances can be mentioned in first instance botulinum toxins. Botulinum toxin is the most lethal natural biological agent known to man. About 50 picograms of a commercially available botulinum toxin type A (purified neurotoxin complex) correspond to the LD50 in mice. However, the same toxin has been used at tiny doses for therapeutic purposes in man since the 1980s. To date, it is believed to treat a number of disorders among which can be mentioned the following: blepharospasm, hemifacial spasm, cervical dystonia, cerebral palsy, post- stroke spasticity of the arm or leg, hyperhidrosis (e.g. palmar hyperhidrosis, axillar hyperhidrosis, Frey's syndrome or gustatory sweating), wrinkles (e.g. glabellar lines), urinary retention, urinary incontinence, benign prostatic hyperplasia, anal, fissure, skin wounds, type 2 diabetes, articular pathologies, acne and many others.
Other botulinum toxins share the same therapeutic properties of botulinum toxin type A (e.g. botulinum toxins of types B, C1, D, E, F and G); however, only botαlinum toxin type A and botulinum toxin type B are currently marketed. Botulinum toxin type A is mainly commercially available from Ipsen (Dysport®, Ipsen Limited, Slough, UK) and Allergan (BOTOX®, Allergan Inc., Irvine, CA, USA) whereas botulinum toxin type B is sold by Elan (Myobloc®/Neurobloc®, Solstice Neurosciences Inc., San Diego, CA, USA).
PCT patent application WO 03/084567 (or US patent 6,767,544) teaches the use of botulinum toxin to treat a cardiovascular disorder by administering an effective amount of a botαlinum toxin directly to a blood vessel of a patient (notably to prevent restenosis). In this patent application, "cardiovascular" is defined as "pertaining to blood vessels, for example, blood vessels of the heart".
The Applicant has now surprisingly found that a pre-synaptic neuromuscular blocking substance, and in particular a botulinum toxin, could also be used for the treatment or prevention of heart rhythm disorders, notably heart fibrillation disorders.
By pre-synaptic neuromuscular blocking substance should be understood in the present application a substance that prevents and/or inhibits transmission of the chemical messages and signals involved in pre-synaptic neuromuscular activity. Examples of such pre-synaptic neuromuscular blocking substances are substances that inhibit acetylcholine (ACh) synthesis or release; those include notably biological toxins (such as botulinum neurotoxins and bungarotoxins but also any synthetic analogue thereof having the same activity like recombinantly engineered botulinum toxins) and chemicals (such as hemicholinium or triethylcholine which inhibit ACh synthesis, aminoglycoside antibiotics which inhibit ACh release or tubocurarine and similar compounds). Preferred pre-synaptic neuromuscular blocking substances according to this invention will be botulinum neurotoxins and bungarotoxins (α-bungarotoxin being preferred among the bungarotoxins).
By botulinum neurotoxins (or botulinum toxins) is meant in the present application botulinum neurotoxin complexes (whether of type A, B, C, D, E, F or G), high purity botulinum neurotoxins (whether of type A, B, C, D, E, F or G) as well as any recombinantly engineered botulinum toxin having similar or better properties than the naturally occurring botulinum toxins or the purified forms thereof. Botulinum toxin type A includes all types of botulinum toxin type A, including A1, A2 and A3, botulinum toxin type C includes all types of botulinum toxin type C, including C1 or C2; the same applies mutatis mutandis to the other serotypes of toxins.
By botulinum neurotoxin complex (whether of type A, B, C, D, E, F or G) should be understood in the present application a botulinum neurotoxin (whether of type A, B, C, D, E, F or G) associated with at least another non-toxic protein.
By high purity botulinum neurotoxin (whether of type A, B, C, D, E, F or G) is meant, in the present application, botulinum neurotoxin (whether of type A, B, C, D, E, F or G) outside from complexes including at least another protein. In other words, a high purity botulinum neurotoxin (type A, B, C, D, E, F or G) does not contain significant quantities of any other Clostridium spp derived protein than botulinum neurotoxin (type A, B, C, D, E, F or G).
Preferably, the pre-synaptic neuromuscular blocking substance will be a botulinum toxin. More preferably, the botulinum toxin will be selected from the group consisting of botulinum toxin type A, botulinum toxin type B and botulinum toxin type F. Even more preferably, the botulinum toxin will be selected from the group consisting of botulinum toxin type A and botulinum toxin type B. In particular, the botulinum toxin will be botulinum toxin type A.
According to the instant invention, the heart rhythm disorders are preferably heart fibrillation disorders. Heart fibrillation disorders are preferably selected from the group consisting of atrial fibrillation and ventricular fibrillation.
According to a first variant of the invention, the heart fibrillation disorder intended to be treated or prevented is atrial fibrillation.
Atrial fibrillation can manifest several ways. Older people typically get chronic atrial fibrillation. Excess adrenaline causes adrenergic atrial fibrillation. Neurogenic atrial fibrillation stems from an imbalance in the nervous system's regulation of the heart. Men between 30 and 50 are subject to vagal atrial fibrillation after a meal or at rest. Young people can be affected by lone or primary atrial fibrillation, which presents no identifiable cause; paroxysmal atrial fibrillation, which causes intermittent attacks of variable length; and rare familial atrial fibrillation. Atrial fibrillation may also be associated with other cardiac muscles or valvula disorders such as cardiomyopathy, cardiac insufficiency, ischemia and/or infarction disorders (e.g. aortic, tricuspid, pulmonary or mitral valvula stenosis) or insufficiency or conduction disorders.
According to a second variant of the invention, the heart fibrillation disorder intended to be treated or prevented is ventricular fibrillation.
The administration locus for the pre-synaptic neuromuscular blocking substance should be the location of the source of the irregular rhythm. In order to find said source, one could for example perform an electrophysiological study.
According to one variant of the invention, the pre-synaptic neuromuscular blocking substance is used to treat the fibrillation disorder. In such case, a pre-synaptic neuromuscular blocking substance with short onset of action like voltage-gated sodium channel blockers will be preferred.
According to another variant of the invention, the pre-synaptic neuromuscular blocking substance is used to prevent recurrence of the fibrillation disorder. In such case, a pre-synaptic neuromuscular blocking substance with a prolonged duration of action (e.g. botulinum toxin type A or botulinum toxin type F, and preferably botulinum toxin type A) will be preferred.
The dose of pre-synaptic neuromuscular blocking substance which shall be needed for the treatment of the disorders mentioned above varies depending on the disorder to be treated, administration mode, age and body weight of the patient to be treated and health state of the latter, and it is the treating physician or veterinary that will eventually make
the decision. Such a quantity determined by the treating physician or veterinarian is called here "therapeutically efficient quantity".
For botulinum neurotoxin complex (type A, B, C, D, E, F or G) or high purity botulinum neurotoxin (type A5 B, C, D, E, F or G), this therapeutically efficient dose is often expressed as a function of the corresponding LD50. By LD50 should be understood in the present application the median intraperitoneal dose in mice injected with botulinum neurotoxin complex (type A, B, C, D5 E5 F or G) or high purity botulinum neurotoxin (type A5 B, C5 D5 E5 F or G) that causes death of half of said mice within 96 hours (see the "Mouse toxicity assay" protocol under "ANALYTICAL METHODS").
However, it is believed that, for botulinum toxin type A5 this effective amount could be about 10 to 500 LD50 units and preferably about 50 to 250 LD50 units:
The approximate effective amounts for the other pre-synaptic neuromuscular blocking substances can easily be deduced by one skilled in the art (by a conversion based on his knowledge of the respective activities of said substances).
Of course, the pre-synaptic neuromuscular blocking substance treatment according to the instant invention may be combined with the other current treatments of heart rhythm disorders (such as pacemaker, anticoagulants or other common medications for the treatment of heart rhythm disorders).
The pre-synaptic neuromuscular blocking substance treatment may optionally be associated with an analgesic treatment (e.g. by administration of an analgesic substance like morphine) prior to, at the same time or shortly after the toxin is administered.
The term "about" refers to an interval around the considered value. As used in this patent application, "about X" means an interval from X minus 10% of X to X plus 10% of X, and preferably an interval from X minus 5% of X to X plus 5% of X and about "about X to Y" means an interval from X minus 10%' of (X+Y) to Y plus 10% of (X+Y), and preferably an interval from X minus 5% of (X+Y) to Y plus 5% of (X+Y).
Unless they are defined differently, all the technical and scientific terms used here have the same meaning as that usually understood by an ordinary specialist in the field to which this invention belongs. Similarly, all publications, patent applications, all patents and all other references mentioned here are incorporated by way of reference.
The following example is presented to illustrate the above and must in no case be considered as a limit to the scope of the invention.
Example: Treatment of atrial fibrillation:
A male patient in his sixties has had several episodes of atrial fibrillation. An electrophysiological study is performed to determine the location of the source of the irregular rhythm. Injection of 80 LD50 units of a botulinum toxin type A preparation (e.g. Dy sport® from Ipsen Ltd, Slough, UK - the product being used following the reconstitution protocol of the manufacturer) into the key trigger points found for this patient is carried out to correct the heart rhythm disorder. As a result, the arrhythmic episodes were eliminated for a period of at least three months.
ANALYTICAL METHODS
Mouse toxicity assay
A mouse toxicity assay can be used to measure the toxicity of botulinum neurotoxin complex (type A, B, C, D, E, F or G) or high purity botulinum neurotoxin (type A, B, C, D, E, F or G). hi the assay, a standard diluent will be used to prepare a range of dilutions at or about the estimated LD50 value. The range and scale of dilutions is arranged so as to establish an accurate LD50 value.
Mice are injected intraperitoneally with a known arid standardised volume of diluted toxin. After 96 hours, the number of deaths and survivors in each dilution group will be recorded. The LD50 value is the median dose which kills half of the injected animals within 96 hours.
Claims
1. Use of a pre-synaptic neuromuscular blocking substance for preparing a medicament intended to prevent or treat heart rhythm disorders.
2. Use according to claim 1, characterised in that the heart rhythm disorders are heart fibrillation disorders.
3. Use according to claim 2, characterised in that the heart rhythm disorders are atrial fibrillation disorders.
4. Use according to claim 2, characterised in that the heart rhythm disorders are ventricular fibrillation disorders.
5. Use according to one of claims 1 to 4, characterised in that the pre-synaptic neuromuscular blocking substance is selected from the group consisting of botulinum neurotoxins, synthetic analogues of botulinum neurotoxins, bungarotoxins, synthetic analogues of bungarotoxins, hemicholinium, triethylcholine and tubocurarine.
6. Use according to claim 5, characterised in that the pre-synaptic neuromuscular blocking substance is a botulinum toxin.
7. Use according to claim 6, characterised in that the botulinum neurotoxin is selected from the group consisting of botulinum toxin type A, botulinum toxin type B and botulinum toxin type F.
8. Use according to claim 7, characterised in that the botulinum neurotoxin is selected from the group consisting of botulinum toxin type A and botulinum toxin type B.
9. Use according to claim 8, characterised in that the botulinum neurotoxin is botulinum toxin type A.
10. Use according to one of claims 1 to 9, characterised in that the pre-synaptic neuromuscular blocking substance is associated with an analgesic substance.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05798307A EP1807104A1 (en) | 2004-10-29 | 2005-10-28 | Botulinum toxin therapy of heart rhythm disorders |
| US11/666,639 US20070259002A1 (en) | 2004-10-29 | 2005-10-28 | Botulinum Toxin Therapy of Heart Rhythm Disorders |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0424048A GB2419817A (en) | 2004-10-29 | 2004-10-29 | Treatment of cardiac fibrillation disorders |
| GB0424048.7 | 2004-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006046065A1 true WO2006046065A1 (en) | 2006-05-04 |
Family
ID=33515780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2005/004182 WO2006046065A1 (en) | 2004-10-29 | 2005-10-28 | Botulinum toxin therapy of heart rhythm disorders |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20070259002A1 (en) |
| EP (1) | EP1807104A1 (en) |
| GB (1) | GB2419817A (en) |
| WO (1) | WO2006046065A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014184746A1 (en) * | 2013-05-15 | 2014-11-20 | Bosti Trading Ltd. | Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof |
| WO2024102345A1 (en) * | 2022-11-07 | 2024-05-16 | Allergan, Inc. | Prevention of post-operative atrial fibrillation with a botulinum toxin |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10973873B1 (en) | 2019-10-18 | 2021-04-13 | Penland Foundation | Treatment of asthma using botulinum toxin |
| US10960061B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of amyotrophic lateral sclerosis using botulinum toxin |
| US11090371B1 (en) | 2019-10-18 | 2021-08-17 | Penland Foundation | Treatment of cirrhosis using botulinum toxin |
| US10967052B1 (en) | 2019-10-18 | 2021-04-06 | Penland Foundation | Treatment of dyslexia using botulinum toxin |
| US11241479B2 (en) | 2019-10-18 | 2022-02-08 | Penland Foundation | Treatment methods using botulinum toxins |
| US10987411B1 (en) | 2019-10-18 | 2021-04-27 | Penland Foundation | Treatment of chronic obstructive pulmonary disease using botulinum toxin |
| US10960060B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of cardiac arrhythmia using botulinum toxin |
| KR102520625B1 (en) | 2019-10-18 | 2023-04-12 | 펜랜드 파운데이션 | botulinum toxin for use in therapy |
| WO2023287728A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of diabetes and chronic pancreatitis using botulinum toxin |
| WO2023287729A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of acute and chronic kidney disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001010458A1 (en) * | 1999-08-10 | 2001-02-15 | Allergan Sales, Inc. | Use of neurotoxin for treating cardiac muscle disorders |
| WO2003084567A1 (en) * | 2002-04-01 | 2003-10-16 | Allergan, Inc. | Use of botulinum toxin for treating cardiovasular diseases |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049111A2 (en) * | 2003-11-13 | 2005-06-02 | Symphony Medical, Inc. | Control of cardiac arrhythmias by modification of neuronal conduction within fat pads of the heart |
-
2004
- 2004-10-29 GB GB0424048A patent/GB2419817A/en not_active Withdrawn
-
2005
- 2005-10-28 EP EP05798307A patent/EP1807104A1/en not_active Withdrawn
- 2005-10-28 US US11/666,639 patent/US20070259002A1/en not_active Abandoned
- 2005-10-28 WO PCT/GB2005/004182 patent/WO2006046065A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001010458A1 (en) * | 1999-08-10 | 2001-02-15 | Allergan Sales, Inc. | Use of neurotoxin for treating cardiac muscle disorders |
| WO2003084567A1 (en) * | 2002-04-01 | 2003-10-16 | Allergan, Inc. | Use of botulinum toxin for treating cardiovasular diseases |
Non-Patent Citations (2)
| Title |
|---|
| DOWDY E G ET AL: "Effect of neuromuscular blocking agents on isolated digitalized mammalian hearts.", ANESTHESIA AND ANALGESIA. 1965 SEP-OCT, vol. 44, no. 5, September 1965 (1965-09-01), pages 608 - 617, XP009058984, ISSN: 0003-2999 * |
| KARHUNEN U ET AL: "The effect of tubocurarine and alcuronium on suxamethonium-induced changes in cardiac rate and rhythm.", ACTA ANAESTHESIOLOGICA SCANDINAVICA. 1972, vol. 16, no. 1, 1972, pages 3 - 10, XP009058990, ISSN: 0001-5172 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014184746A1 (en) * | 2013-05-15 | 2014-11-20 | Bosti Trading Ltd. | Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof |
| CN105209014A (en) * | 2013-05-15 | 2015-12-30 | 波斯蒂贸易有限公司 | Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof |
| US10258673B2 (en) | 2013-05-15 | 2019-04-16 | Bosti Trading Ltd. | Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof |
| EP3750525A1 (en) * | 2013-05-15 | 2020-12-16 | Bosti Trading Ltd. | Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof |
| WO2024102345A1 (en) * | 2022-11-07 | 2024-05-16 | Allergan, Inc. | Prevention of post-operative atrial fibrillation with a botulinum toxin |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1807104A1 (en) | 2007-07-18 |
| US20070259002A1 (en) | 2007-11-08 |
| GB2419817A (en) | 2006-05-10 |
| GB0424048D0 (en) | 2004-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070259002A1 (en) | Botulinum Toxin Therapy of Heart Rhythm Disorders | |
| Nawrocki et al. | Botulinum toxin: pharmacology and injectable administration for the treatment of primary hyperhidrosis | |
| Lowe | Botulinum toxin type A for facial rejuvenation: United States and United Kingdom perspectives | |
| JP4937758B2 (en) | Botulinum toxin treatment for skin disorders | |
| EP3777837A1 (en) | Liquid formulation containing botulinum toxin and stabilizing agent, and preparation method therefor | |
| Gelbard et al. | Primary pediatric hyperhidrosis: a review of current treatment options | |
| EP2977058A1 (en) | Methods for treating adhesive capsulitis | |
| Cocco et al. | Recent developments in clinical trials of botulinum neurotoxins | |
| Harper et al. | Botulinum toxin and its applications in the lower urinary tract. | |
| WO2006028724A1 (en) | Stretch mark treatment with botulinum toxic | |
| EP3932938A1 (en) | Botulinum toxin type a complex, and formulation thereof and usage method therefor | |
| EP1773378B1 (en) | Use of botulinum toxin for the preparation of a medicament for the treatment of lithiasis of salivary gland, gall bladder, kidney, or pancreas | |
| US8337862B2 (en) | Method for treating knee joint pain caused by saphenous nerve entrapment | |
| JP2011184462A (en) | Use of botulinum neurotoxin to alleviate various disorders | |
| Markey | Dysport | |
| Ward et al. | Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function | |
| JP2011157331A (en) | Botulinus toxin formulation capable of high-dose administration | |
| TWI739368B (en) | Type A botulinum toxin complex, its formulation and method of use | |
| Bayrak et al. | Use of botulinum toxin in urology: a literature review: Ürolojide botulinum toksin uygulamaları: literatür derlemesi | |
| Cornelia et al. | Botulinum toxins: transformation of a toxin into a treatment | |
| Rauh et al. | Botolinum neurotoxin: its history and use in dermatology. | |
| CA2190564C (en) | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders | |
| Bayrak et al. | Use of botulinum toxin in urology: a literature | |
| Gnanaruban et al. | Patients satisfaction and symptomatic relief following botulinum toxin A injection for hemifacial spasm and muscle palsies | |
| Olivari | ST-elevation acute myocardial infarction: can we improve the results of primary percutaneous coronary intervention? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MD MG MK MN MW MX MZ NA NG NO NZ OM PG PH PL PT RO RU SC SD SG SK SL SM SY TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2005798307 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11666639 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWP | Wipo information: published in national office |
Ref document number: 2005798307 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 11666639 Country of ref document: US |